FDA scientists opposed Trump administration’s move to ease peptide access

Synopsis

Decisions over compounding have long rested with the FDA, not HHS. The FDA has warned Americans about safety risks of unproven peptides

Automatically extracted from the original page. This is a short summary, not the full story, and may omit important detail.